This story is unavailable.

Drug pricing in America has gained a lot of attention recently, with the price tags of everything from new cancer medicines to EpiPens skyrocketing. Many have wondered: Is it fair to make life-saving drugs so costly?

Mylan (EpiPen) and Turing Pharmaceuticals (Daraprim) answer “because we can.” Lilly and NovoNordisk have the same answer for their vat-brewed synthetic insulins selling for a hundred dollar a pen syringe (they ought to have gotten cheaper than insulin made from cow and pig pancreases by now). The collusive DEA/Big Pharma price hikes on morphine and oxycodone for severe pain also happened “because we can.”

Like what you read? Give Jean Lafitte a round of applause.

From a quick cheer to a standing ovation, clap to show how much you enjoyed this story.